These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38141488)

  • 1. Face to face among different chemo-immunotherapy combinations in the first line treatment of patients with advanced non-small cell lung cancer: Results of an international expert panel meeting by the italian association of thoracic oncology (AIOT).
    Gridelli C; Peters S; Mok T; Garassino M; Paz-Ares L; Attili I; de Marinis F
    Lung Cancer; 2024 Jan; 187():107441. PubMed ID: 38141488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy in the first-line treatment of elderly patients with advanced non-small-cell lung cancer: results of an International Experts Panel Meeting by the Italian Association of Thoracic Oncology (AIOT).
    Gridelli C; Peters S; Velcheti V; Attili I; de Marinis F
    ESMO Open; 2023 Apr; 8(2):101192. PubMed ID: 36965261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-line immunotherapy in advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an International Expert Panel Meeting by the Italian Association of Thoracic Oncology.
    Gridelli C; Peters S; Mok T; Forde PM; Reck M; Attili I; de Marinis F
    ESMO Open; 2022 Feb; 7(1):100355. PubMed ID: 34922299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with or without PD-L1 selection: A systematic review and network meta-analysis.
    Li Y; Liang X; Li H; Chen X
    Chin Med J (Engl); 2023 Sep; 136(18):2156-2165. PubMed ID: 37596898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative efficacy of chemoimmunotherapy versus immunotherapy for advanced non-small cell lung cancer: A network meta-analysis of randomized trials.
    Pathak R; De Lima Lopes G; Yu H; Aryal MR; Ji W; Frumento KS; Wallis CJD; Klaassen Z; Park HS; Goldberg SB
    Cancer; 2021 Mar; 127(5):709-719. PubMed ID: 33119177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.
    Dafni U; Tsourti Z; Vervita K; Peters S
    Lung Cancer; 2019 Aug; 134():127-140. PubMed ID: 31319971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the profiles of first-line PD-1/PD-L1 inhibitors for advanced NSCLC lacking driver gene mutations: a systematic review and Bayesian network meta-analysis.
    Wenfan F; Manman X; Xingyuan S; Zeyong J; Jian Z; Lu D
    Ther Adv Chronic Dis; 2023; 14():20406223231189224. PubMed ID: 37841212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maintenance treatment of advanced non-small-cell lung cancer: results of an international expert panel meeting of the Italian association of thoracic oncology.
    Gridelli C; de Marinis F; Di Maio M; Ardizzoni A; Belani CP; Cappuzzo F; Ciardiello F; Fidias P; Paz-Ares L; Perrone F; Pirker R; De Petris L; Stahel R
    Lung Cancer; 2012 Jun; 76(3):269-79. PubMed ID: 22266040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy-chemotherapy combinations for non-small cell lung cancer: current trends and future perspectives.
    Cella E; Zullo L; Marconi S; Rossi G; Coco S; Dellepiane C; Alama A; Rozeboom L; Bennicelli E; Parisi F; Sacco G; Barletta G; Zinoli L; Tagliamento M; Pronzato P; Genova C
    Expert Opin Biol Ther; 2022 Oct; 22(10):1259-1273. PubMed ID: 35994596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Evaluation of Response to Immune Checkpoint Inhibitor Monotherapy or 
Combination with Chemotherapy for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression].
    Li H; Qin N; Yu M; Ma L; Wu Y; Zhang H; Zhang X; Li X; Wang J
    Zhongguo Fei Ai Za Zhi; 2021 Mar; 24(3):161-166. PubMed ID: 33819965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of PROphet Test in Changing Physicians' Therapeutic Decision-Making for Checkpoint Immunotherapy in Non-Small-Cell Lung Cancer.
    Gandara DR; Subramanian J; Santos ES; Brody Y; Sela I; Elon Y; Harel M; Reiner-Benaim A; Lahav C; McGregor K
    Clin Lung Cancer; 2024 Sep; 25(6):e252-e261.e4. PubMed ID: 39034168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world performance of blood-based proteomic profiling in first-line immunotherapy treatment in advanced stage non-small cell lung cancer.
    Rich P; Mitchell RB; Schaefer E; Walker PR; Dubay JW; Boyd J; Oubre D; Page R; Khalil M; Sinha S; Boniol S; Halawani H; Santos ES; Brenner W; Orsini JM; Pauli E; Goldberg J; Veatch A; Haut M; Ghabach B; Bidyasar S; Quejada M; Khan W; Huang K; Traylor L; Akerley W
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34706885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
    Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study protocol of KeyPemls-004: A phase 2 study of pembrolizumab in combination with plinabulin and docetaxel in previously treated patients with metastatic non-small cell lung cancer and progressive disease (PD) after immunotherapy (PD-1/PD-L1 inhibitor) alone or in combination with platinum-doublet chemotherapy.
    Liu J; Chen M; Gao X; Liu X; Zhao J; Pan R; Zhong W; Xu Y; Wang M
    Thorac Cancer; 2023 Mar; 14(8):773-778. PubMed ID: 36725772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy in Advanced Non-Small Cell Lung Cancer.
    Huang J; Reckamp KL
    Semin Respir Crit Care Med; 2020 Jun; 41(3):400-408. PubMed ID: 32450594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent issues in first-line treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology.
    Gridelli C; Ardizzoni A; Douillard JY; Hanna N; Manegold C; Perrone F; Pirker R; Rosell R; Shepherd FA; De Petris L; Di Maio M; de Marinis F
    Lung Cancer; 2010 Jun; 68(3):319-31. PubMed ID: 20036027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of nivolumab combined to immunotherapy and/or chemotherapy in the first-line treatment of advanced Non Small Cell Lung Cancer.
    Rocco D; Della Gravara L; Battiloro C; Gridelli C
    Expert Opin Biol Ther; 2021 Mar; 21(3):303-309. PubMed ID: 33355496
    [No Abstract]   [Full Text] [Related]  

  • 20. A composite biomarker of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancers.
    Ayers KL; Ma M; Debussche G; Corrigan D; McCafferty J; Lee K; Newman S; Zhou X; Hirsch FR; Mack PC; Liu JJ; Schadt EE; Chen R; Li SD
    BMC Cancer; 2021 Apr; 21(1):441. PubMed ID: 33882890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.